GLMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Galmed Pharmaceuticals Ltd (GLMD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive developments in research collaborations, the company's financials remain weak, and there are no strong technical or trading signals to support a buy decision. The stock's recent price volatility and lack of clear upward momentum make it more prudent to hold off on investing at this time.
The MACD is positive but contracting, indicating weak bullish momentum. RSI is neutral at 65.759, and moving averages are converging, showing no clear trend. Key support is at 0.501, and resistance is at 1.101. The stock is trading below the pivot point of 0.801, suggesting limited upward potential in the short term.
Galmed Pharmaceuticals has partnered with Tel Aviv University to evaluate Aramchol for treating metastatic brain cancer, expanding its focus into oncology. This collaboration could bring long-term growth opportunities if successful.
The company's financials remain weak, with no revenue growth, negative net income, and declining EPS. Additionally, there are no significant insider or hedge fund trading trends, and the stock's short-term price trend is uncertain.
In Q4 2025, revenue remained at 0 with no growth. Net income improved by 50.14% YoY but remains negative at -$4.82M. EPS dropped by 60% YoY to -0.8, reflecting continued financial struggles. Gross margin remains at 0.
No recent analyst ratings or price target changes available.
